Relay Therapeutics, Inc. (RLAY) Stock Price & Analysis
Relay Therapeutics, Inc. (RLAY) fell 3.40% to USD 18.44 as of July 25, 2026 at 03:51 UTC, according to Nexqual real-time market data.
RLAY last closed at USD 19.09; the session ranged USD 18.26–19.29 on volume of 1,902,823 shares. Market capitalization is $4.02B, with a 52-week range of USD 3.03–20.79 (NGM). Source: Nexqual, July 25, 2026 at 03:51 UTC.
Key Statistics (as of July 25, 2026 at 03:51 UTC)
| Price | USD 18.44 |
|---|---|
| Change | ▼ 3.40% (down) |
| Previous Close | USD 19.09 |
| Open | USD 19.18 |
| Day Range | USD 18.26 – 19.29 |
| 52-Week Range | USD 3.03 – 20.79 |
| Volume | 1,902,823 shares |
| Market Cap | $4.02B |
| Exchange | NGM |
Technical Analysis (RLAY)
Nexqual's technical model rates RLAY "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:51 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 53.82 (neutral) |
| vs SMA50 | Above (USD 16.38) |
| MACD | 0.72 (positive) |
Analyst Ratings (RLAY)
Wall Street analysts rate RLAY "Strong Buy" based on 13 analysts, with a mean price target of USD 26.08 (range USD 20–32), per Nexqual as of July 25, 2026 at 03:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 26.08 |
| High Target | USD 32 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 14 / 0 / 0 |
Earnings (RLAY)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $800,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.41 vs est -0.36 ▼ miss |
| 2025-12-31 | USD -0.31 vs est -0.4 ▲ beat |
| 2025-09-30 | USD -0.43 vs est -0.42 ▼ miss |
| 2025-06-30 | USD -0.41 vs est -0.47 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financials & Fundamentals (RLAY)
| Total Revenue | $10.68M |
|---|---|
| Revenue Growth (YoY) | -60.90% |
| Gross Margin | +0.00% |
| Operating Margin | -2619.67% |
| Profit Margin | +0.00% |
| ROE | -40.01% |
| Debt / Equity | 4.92 |
| Current Ratio | 22.13 |
| Total Cash | $642.07M |
| Total Debt | $31.57M |
| Free Cash Flow | $-121.18M |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Financial Health Score (RLAY)
Nexqual rates Relay Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:51 UTC.
| Growth | Strong — Revenue +53% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $642M cash vs $32M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$121M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -24.7% |
Ownership (RLAY)
| Insider Ownership | +1.37% |
|---|---|
| Institutional Ownership | +88.06% |
| Shares Outstanding | 217.94M |
| Float | 136.14M |
| Short % of Float | +23.02% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
Leadership (RLAY)
Relay Therapeutics, Inc. is led by Sanjiv K. Patel M.A., M.B.A., M.D., MBBS (age 51), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:51 UTC.
| CEO, President & Director | Sanjiv K. Patel M.A., M.B.A., M.D., MBBS (age 51) |
|---|---|
| Founder & Independent Director | Mark Murcko (age 65) |
| Chief Financial Officer | Thomas Catinazzo (age 48) |
| President of Research & Development | Donald A. Bergstrom (age 53) |
| Chief Scientific Officer | Jim Watters |
Major Backers & Investors (RLAY)
Notable institutional backers of Relay Therapeutics, Inc. include SB Investment Advisers (UK) LTD, Commodore Capital Lp, Casdin Capital, LLC, according to Nexqual as of July 25, 2026 at 03:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SB Investment Advisers (UK) LTD | 14.57% |
| Commodore Capital Lp | 8.87% |
| Casdin Capital, LLC | 7.53% |
| Perceptive Advisors Llc | 5.09% |
| Bellevue Group AG | 4.07% |
| Fidelity | 2.95% |
| Nextech Invest, Ltd. | 2.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.17% |
| Vanguard Group | 7.62% |
| State Street | 6.53% |
Source: Nexqual, July 25, 2026 at 03:51 UTC.
From Relay Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
- It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
- The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases.
- It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| NRIX | Nurix Therapeutics, Inc. | USD 23.38 | ▼ 0.93% |
| RVMD | Revolution Medicines, Inc. | USD 189.23 | ▲ 3.39% |
| PCVX | Vaxcyte, Inc. | USD 54.66 | ▼ 2.39% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:51 UTC. This page is informational and not investment advice.